

Supplemental Table 2. Additional Clinical Data for Comparator Patients

Subject	Pre Chemoradiation Chemo			Tumor Resection		TNM Staging				Survival	
	FOLFIRINOX	Gem/Abrax	Gemcitabine	Pre	Post	T	N	M	Stage	Progression Free	Overall
1	-	-	-	-	+	2	0	0	IB	26.5	54.6
2	-	-	-	-	-	3	0	0	IIA	2.1	46.6
3	-	-	-	-	-	2	1	0	IIB	5.7	22.2
4	-	-	-	-	-	3	1	0	IIB	19.3	21.4
5	-	-	-	-	-	3	0	0	IIA	10.7	20.0
6	-	-	-	-	-	4	1	0	III	3.4	17.2
7	-	-	-	-	+	3	0	0	IIA	9.6	12.7
8	-	-	-	-	-	3	0	0	IIA	3.0	12.7
9	-	-	-	-	-	4	0	0	III	4.4	8.0
10	-	-	-	-	-	3	1	0	IIB	4.6	7.8
11	-	-	-	-	-	3	1	1	IV	2.5	4.9
12	-	-	-	-	-	3	0	0	IIA	2.2	4.5
13	-	-	-	-	-	3	0	0	IIA	2.4	3.8
14	-	-	+	-	-	4	1	0	III	1.9	3.1
15	+	-	-	-	-	3	1	0	IIB	8.7	16.1
16	-	-	-	-	-	2	1	0	IIB	3.9	5.3
17	-	-	-	-	-	3	0	0	IIA	11.7	12.7
18	-	-	-	-	-	3	1	0	III	4.6	5.8
19	-	-	-	-	-	4	1	0	III	8.8	18.3